Company News »

Ignyta Announces Two Entrectinib Phase I Data Presentations and Webcast Management Presentation at the 2015 ASCO Annual Meeting

Business Wire
Share on StockTwits
Published on

Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the publication of two abstracts for the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). Both abstracts were accepted for poster presentations, with one of the abstracts also being selected for a poster discussion session. Both of the poster presentations relate to the results of Phase I clinical trials of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to TrkA, TrkB, TrkC, ROS1 or ALK, and will be held on May 30, 2015, in Chicago, Illinois.

“We are honored that the ASCO Scientific Program Committee has selected the abstracts describing exciting data from our two Phase I clinical trials of entrectinib for poster presentations and a poster discussion session,” said Pratik Multani, M.D., Chief Medical Officer of Ignyta. “We are looking forward to sharing updated data from these clinical trials in this prestigious scientific forum, and to discussing the data and our future clinical development plans for entrectinib with key scientific and clinical experts during the ASCO meeting.”

Details of the presentations are as follows:

Title:

ALKA-372-001: First-in-human, Phase I study of entrectinib – an oral pan-Trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. (Abstract number 2517, Poster number 233)

Date/time: Saturday, May 30, 2015, 8:00 AM – 11:30 AM, Central time (Poster Presentation)
Saturday, May 30, 2015, 1:15 PM – 2:30 PM, Central time (Poster Discussion Session)
Title:

STARTRK-1: Phase 1/2a study of entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. (Abstract number 2596, Poster number 312)

Date/time: Saturday, May 30, 2015, 8:00 AM – 11:30 AM, Central time (Poster Presentation)

In addition, Ignyta announced that it will host a reception in Chicago, Illinois, on Sunday, May 31, 2015, at which its management team will make a presentation relating to the entrectinib Phase I data, the company’s plans for further development of entrectinib and other company highlights. The presentation will take place at 6:30 PM, Central time. A live webcast of the event will be available at http://register.webcastgroup.com/L4/?wid=05682410667. A live webcast of the event will also be available in the Investors section of the company’s website at http://investor.ignyta.com, and will be archived and available at that site for 14 days.

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a precision oncology biotechnology company pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The company’s goal with this Rx/Dx approach is to discover, develop and commercialize new drugs that target activated cancer genes and pathways for the customized treatment of cancer, as well as novel chemotherapeutics that can potentially provide additional benefit to cancer patients. It aims to achieve this goal by pairing its product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients who are most likely to benefit from the precisely targeted drugs the company develops. For more information, please visit: www.ignyta.com.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the development of Ignyta’s product candidates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; Ignyta’s ability to develop, complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in Ignyta’s plans to develop and commercialize its product candidates; the potential for final results of the ongoing Phase I clinical trials of entrectinib, or any future clinical trials of entrectinib or other product candidates, to differ from preliminary or expected results; Ignyta’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Ignyta’s ability to obtain and maintain intellectual property protection for its product candidates; the risk that orphan drug exclusivity may not effectively protect a product from the competition and that such exclusivity may not be maintained; the potential for the company to fail to maintain the CLIA registration of its diagnostic laboratory or to fail to achieve full CLIA accreditation of such laboratory; the loss of key scientific or management personnel; competition in the industry in which Ignyta operates; and market conditions. These forward-looking statements are made as of the date of this press release, and Ignyta assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the company files with the SEC available at www.sec.gov, including without limitation Ignyta’s Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent Quarterly Reports on Form 10-Q.

Share on StockTwits


Iron FX 1.11156/1.11128 2.8
XM Markets 1.09948/1.09928 2
FxPro 1.10184/1.10171 1.3
FXCM 1.13943/1.13912 3.1